ipilimumab,nivolumab,durvalumab,paclitaxel,vinorelbine,carboplatin,cisplatin,gemcitabine,docetaxel,pemetrexed
bms,astrazeneca
['aegean', 'cm816']
the #oncoalerttoptweet day 3 #aacr23 tweet by our oncoalert faculty aegean 3yr 63% efs data (cpr 17%) presented comparable to #cm816 we shouldn t do cross-trial comparisons but we can t help ourselves and wonder: is all the benefit of io seen upfront 
🌐 Worldwide Network of Oncology Professionals & Patient Advocates with the common goal of ending cancer, we are Oncology360 degrees 🌎 We are #OncoAlert 🚨